Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 15;303(4):R449-58.
doi: 10.1152/ajpregu.00016.2012. Epub 2012 Jun 13.

8-OH-DPAT abolishes the pulmonary C-fiber-mediated apneic response to fentanyl largely via acting on 5HT1A receptors in the nucleus tractus solitarius

Affiliations

8-OH-DPAT abolishes the pulmonary C-fiber-mediated apneic response to fentanyl largely via acting on 5HT1A receptors in the nucleus tractus solitarius

Jianguo Zhuang et al. Am J Physiol Regul Integr Comp Physiol. .

Abstract

Intravenous bolus injection of morphine causes a vagal-mediated brief apnea (∼3 s), while continuous injection, via action upon central μ-opioid receptor (MOR), arrests ventilation (>20 s) that is eliminated by stimulating central 5-hydroxytryptamine 1A receptors (5HT(1A)Rs). Bronchopulmonary C-fibers (PCFs) are essential for triggering a brief apnea, and their afferents terminate at the caudomedial region of the nucleus tractus solitarius (mNTS) that densely expresses 5HT(1A)Rs. Thus we asked whether the vagal-mediated apneic response to MOR agonists was PCF dependent, and if so, whether this apnea was abolished by systemic administration of 8-hydroxy-2-(di-n-propylamino)tetral (8-OH-DPAT) largely through action upon mNTS 5HT(1A)Rs. Right atrial bolus injection of fentanyl (5.0 μg/kg, a MOR agonist) was performed in the anesthetized and spontaneously breathing rats before and after: 1) selective blockade of PCFs' conduction and subsequent bivagotomy; 2) intravenous administration of 5HT(1A)R agonist 8-OH-DPAT; 3) intra-mNTS injection of 8-OH-DPAT; and 4) intra-mNTS injection of 5HT(1A)R antagonist WAY-100635 followed by 8-OH-DPAT (iv). We found the following: First, fentanyl evoked an immediate apnea (2.5 ± 0.4 s, ∼6-fold longer than the baseline expiratory duration, T(E)), which was abolished by either blocking PCFs' conduction or bivagotomy. Second, this apnea was prevented by systemic 8-OH-DPAT challenge. Third, intra-mNTS injection of 8-OH-DPAT greatly attenuated the apnea by 64%. Finally, intra-mNTS microinjection of WAY-100635 significantly attenuated (58%) the apneic blockade by 8-OH-DPAT (iv). We conclude that the vagal-mediated apneic response to MOR activation depends on PCFs, which is fully antagonized by systemic 8-OH-DPAT challenge largely via acting on mNTS 5HT(1A)Rs.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
A: typical recordings showing the fentanyl-evoked cardiorespiratory activities and their recoveries. fR, respiratory frequency; VE, minute ventilation. B: typical recordings showing the fentanyl-evoked apneic and cardiovascular responses before (CON) and after perineural treatment of the vagi with capsaicin (pCAP) and subsequent bivagotomy in an anesthetized rat. C: typical recordings of the cardiorespiratory responses to fentanyl before and after perineural treatment of the vagi with vehicle for twice (pVEH1 and pVEH2) in another rat. The traces are arterial blood pressure (ABP), heart rate (HR), and tidal volume (VT). Arrows point to the onset of bolus injection of fentanyl (5.0 μg/kg) into the right atrium.
Fig. 2.
Fig. 2.
Group data of the fentanyl-evoked expiratory duration (TE) prolongation and cardiovascular responses before and after perineural treatment of the vagi with capsaicin (pCAP) and subsequent bivagotomy (A, n = 7) or after twice perineural treatments of the vagi with vehicle (pVEH1 and pVEH2; B, n = 6). Values are means ± SE; **P < 0.01, compared with the baseline values (before injecting fentanyl into the right atrium); ‡P < 0.01, compared with control (CON = without manipulation of vagi). MABP, mean arterial blood pressure.
Fig. 3.
Fig. 3.
Baseline cardiorespiratory activities (CON) and their responses to systemic 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) challenge (DPAT). n = 9; values are means ± SE; *P < 0.05 and **P < 0.01, vs. CON.
Fig. 4.
Fig. 4.
Fentanyl-induced TE prolongation and cardiovascular responses before and after intravenous administration of DPAT (A) or vehicle (VEH, B). n = 9; values are means ± SE; *P < 0.05 and **P < 0.01, compared with the baseline values (before injecting fentanyl into the right atrium); ‡P < 0.01, compared with CON (before systemic DPAT challenge).
Fig. 5.
Fig. 5.
Fentanyl-evoked TE prolongation before and after intra-caudomedial nucleus of solitary tract (mNTS) microinjection of DPAT without and with local WAY-100635 pretreatment (WAY+DPAT). A: typical recordings with arrows indicating the onset of bolus injections of fentanyl via the right atrium. B: group data. n = 7; values are means ± SE; **P < 0.01, compared with baseline values (“0”) obtained before injecting fentanyl into the right atrium; †P < 0.05 and ‡P < 0.01, compared with control (CON = without systemic or local treatment) or WAY+DPAT. C: bilateral microinjection locations labeled by fluorescent microbeads. 10N, dorsal motor nucleus of vagus; 12N, hypoglossal nucleus; CC, central canal; Gr, gracile nucleus.
Fig. 6.
Fig. 6.
Typical recordings showing the effects of microinjecting WAY into the mNTS (A) or the interstitial NTS (iNTS, B) on the apneic blockade by systemic DPAT challenge in two rats, respectively. VEH, local microinjection of vehicle; VEH+DPAT or WAY+DPAT, local microinjection of vehicle or WAY followed by systemic DPAT challenge. Arrows point to the onset of bolus injection of fentanyl into the right atrium. C: locations of microbeads microinjected into bilateral iNTS.
Fig. 7.
Fig. 7.
Effects of microinjection of WAY into the mNTS (A) or the iNTS (B) on the apneic blockade by systemic DPAT challenge. CON1, the control of apneic response to fentanyl before systemic DPAT challenge; CON2, the recovery of the apneic response from systemic DPAT challenge; DPAT, intravenous injection of 8-OH-DPAT; WAY+ DPAT, intra-mNTS or -iNTS microinjection of WAY-100635 (WAY) followed by systemic DPAT challenge. n = 8; values are means ± SE; *P < 0.05 and **P < 0.01, compared with the baseline values (before injecting fentanyl into the right atrium); †P < 0.05 and ‡P < 0.01, compared with CON1/CON2 and DPAT.
Fig. 8.
Fig. 8.
Comparison of baseline cardiorespiratory activities and their responses to systemic DPAT challenge before and after pretreating the mNTS with WAY. CON, before intra-mNTS injection of WAY; DPAT, systemic DPAT challenge; WAY, intra-mNTS injection of WAY; WAY+DPAT, intra-mNTS injection of WAY followed by systemic DPAT challenge. n = 8; values are means ± SE; *P < 0.05 and **P < 0.01, compared with CON; †P < 0.05 and ‡P < 0.01, compared with WAY. Note: all data of WAY+DPAT are not significantly different from those of DPAT alone (P > 0.05). PetCO2, end-tidal pressure of carbon dioxide.

Similar articles

Cited by

References

    1. Aicher SA, Goldberg A, Sharma S, Pickel VM. mu-opioid receptors are present in vagal afferents and their dendritic targets in the medial nucleus tractus solitarius. J Comp Neurol 422: 181– 190, 2000 - PubMed
    1. Ballanyi K, Lalley PM, Hoch B, Richter DW. cAMP-dependent reversal of opioid- and prostaglandin-mediated depression of the isolated respiratory network in newborn rats. J Physiol 504: 127– 134, 1997 - PMC - PubMed
    1. Belvisi MG, Hele DJ. Cough Sensors. III. Opioid and cannabinoid receptors on vagal sensory nerves. In: Handbook of Experimental Pharmacology, Berlin, Germany: Springer-Verlag, 2009, vol. 187, p. 63– 76 - PubMed
    1. Berrill JW, Linnasne SJ. Morphine for management of refractory dyspnoea: opiates should be used with caution. BMJ 327: 1288; author reply 1288–1289, 2003. - PMC - PubMed
    1. Bianchi AL, Denavit-Saubie M, Champagnat J. Central control of breathing in mammals: neuronal circuitry, membrane properties, and neurotransmitters. Physiol Rev 75: 1– 45, 1995 - PubMed

Publication types

MeSH terms